Amplia Therapeutics Limited (INNMF)

Market Cap	86.57M +373.9%
Revenue (ttm)	3.31M +46.8%
Net Income	-5.25M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	27,615
Open	0.1810
Previous Close	0.1810
Day's Range	0.1810 - 0.1810
52-Week Range	0.0287 - 0.2724
Beta	0.77
RSI	60.55
Earnings Date	May 29, 2026

About Amplia Therapeutics

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Country: Australia
• Stock Exchange: OTCMKTS
• Ticker Symbol: INNMF

Financial Performance

In fiscal year 2025, Amplia Therapeutics's revenue was 3.78 million, a decrease of -15.03% compared to the previous year's 4.45 million. Losses were -6.57 million, 45.9% more than in 2024.

Financial numbers in AUD